[HTML][HTML] Identification and treatment of T2-low asthma in the era of biologics

…, A Gogali, K Bartziokas, K Kostikas - ERJ Open …, 2021 - Eur Respiratory Soc
Currently, and based on the development of relevant biologic therapies, T2-high is the most
well-defined endotype of asthma. Although much progress has been made in elucidating T2-…

Serum uric acid as a predictor of mortality and future exacerbations of COPD

K Bartziokas, AI Papaioannou… - European respiratory …, 2014 - Eur Respiratory Soc
Serum uric acid is increased in respiratory disease, especially in the presence of hypoxia
and systemic inflammation. We evaluated serum uric acid as a biomarker for prediction of …

Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission

AI Papaioannou, E Fouka, K Bartziokas… - Expert Review of …, 2023 - Taylor & Francis
Introduction In recent years, monoclonal antibodies targeting Type-2 inflammatory pathways
have been developed for severe asthma treatment. However, even when patients are …

The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations

AI Papaioannou, K Bartziokas, S Tsikrika… - European …, 2013 - Eur Respiratory Soc
The impact of depressive symptoms on outcomes of acute exacerbations of chronic obstructive
pulmonary disease (AECOPD) has not been thoroughly evaluated in prospective studies. …

ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations

…, S Ananth, P Bakke, K Bartziokas… - European …, 2022 - Eur Respiratory Soc
Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous
outcomes, often omitting those that are clinically relevant or more important to patients…

Global initiative for chronic obstructive lung disease (GOLD) recommendations: strengths and concerns for future needs

K Bartziokas, A Papaporfyriou, G Hillas… - Postgraduate …, 2023 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is already the third leading cause of death
worldwide and simultaneously a major cause of morbidity and mortality. Global initiative for …

[HTML][HTML] Lactate dehydrogenase, COVID-19 and mortality

K Bartziokas, K Kostikas - Medicina clinica, 2021 - ncbi.nlm.nih.gov
Outbreaks of the COVID-19 epidemic have been causing worldwide health concerns since
November 2019. Until today, over 200 countries have been affected by the COVID-19 …

Statins and outcome after hospitalization for COPD exacerbation: a prospective study

K Bartziokas, AI Papaioannou, M Minas… - Pulmonary …, 2011 - Elsevier
BACKGROUND: Retrospective studies have shown that the use of statins is associated with
reduced mortality and decreased hospitalizations from COPD, but data from prospective …

SARS-Cov-2 infection in severe asthma patients treated with biologics

…, K Samitas, E Zervas, K Kostikas, K Bartziokas… - The Journal of Allergy …, 2022 - Elsevier
Background At the beginning of the pandemic, there have been considerable concerns
regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe …

[HTML][HTML] Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol

…, F Abroug, A Agusti, P Bakke, K Bartziokas… - ERJ open …, 2020 - Eur Respiratory Soc
Randomised controlled trials (RCTs) on the management of COPD exacerbations evaluate
heterogeneous outcomes, often omitting those that are clinically important and patient …